Prevalence of HI-PEITHO–Eligible Patients in the RIETE Registry and Simulated Population-Level Projections for Ultrasound-Facilitated Catheter-Directed Fibrinolysis
Extract Normotensive acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and elevated cardiac biomarkers (ESC intermediate-high risk; AHA/ACC categories C3–D2) is associated with a substantial risk of adverse outcomes. [1, 2] Reported 7-day mortality ranges from 1–2%, while clinical deterioration requiring escalation of care occurs in approximately 5–10% of patients treated with anticoagulation alone. [3, 4] Addressing the longstanding debate regarding the optimal management of intermediate-high-risk PE, the recently published Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO) trial enrolled a risk-enriched cohort with features of cardiorespiratory compromise.
Authors
- Pablo Demelo‐Rodríguez (ORCID: https://orcid.org/0000-0002-3096-4711)
- Sina Rashedi (ORCID: https://orcid.org/0000-0003-0146-5611)
- Romain Chopard (ORCID: https://orcid.org/0000-0002-8358-515X)
- Samuel Zachary Goldhaber (ORCID: https://orcid.org/0000-0002-6450-0448)
- Behnood Bikdeli (ORCID: https://orcid.org/0000-0003-1428-879X)
- the RIETE investigators
- Gregory Piazza (ORCID: https://orcid.org/0000-0003-1407-5276)
- Manuel Monréal (ORCID: https://orcid.org/0000-0002-0494-0767)
- Adriana González-Munera (ORCID: https://orcid.org/0000-0002-4499-2799)
- Mariana Becker Pfeferman (ORCID: https://orcid.org/0000-0002-7486-4915)
- Carmine Siniscalchi (ORCID: https://orcid.org/0000-0002-0613-1074)
Institutions
- University of Parma (IT)
- Brigham and Women's Hospital (US)
- Yale New Haven Hospital (US)
- Harvard University (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Centre Hospitalier Universitaire de Besançon (FR)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1183/23120541.01273-2026
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00